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Aim. The prostate tumor-inducing oncogene (PTI-1), presumably encoding a truncated form of eukaryotic trans-
lation elongation factor 1A1 (eEF1A1), was discovered as a gene overexpressed in prostate tumor samples and
absent in normal tissues. The mechanism of PTI-1 oncogenicity remains obscure.Methods. Several bioinforma-
tics methods were applied to analyze the PTI-1 mRNA structure, translation efficiency and coding potential.
Results. In silico analysis of 5'UTR of its mRNA suggest that PTI-1 mRNA most probably belongs to the class of
templates with low translation efficiency. Additionally, novel open reading frame (ORF) starting with alternati-
ve initiation site situated upstream of the main ORF start codon was found. Finally, the peptide that does not re-
semble eEF1A1 but is partially homologous to relaxin can be synthesized. Conclusions. We suggest that the al-
ternative upstream start codon may initiate synthesis of a peptide (uPTI-1) homologous to relaxin, the hormone
shown to promote the prostate cancer progression. uPTI-1 protein may interact with the respective relaxin-spe-
cific receptors, suggesting that the tumorigenic outcome of PTI-1 is possibly realized via the relaxin-dependent
pathway.
Keywords: prostate cancer, PTI-1, eEF1A1, non-coding RNA, relaxin, ORF, uAUG.
Introduction. Prostate cancer remains one of the most
prevailing reasons of male death in the world. The mo-
lecular events mediating the prostate cancer develop-
ment and progression are still in the focus of laboratory
studies. There is also no reliable diagnostic tool for the
prostate cancer detection at early stages. One of the most
intriguing questions discussed during last 20 years is a
role of the putative oncogene PTI-1 in the onset of pro-
state tumorogenesis.
The prostate tumor inducing gene (PTI-1) was ini-
tially identified by differential RNA display analysis of
cDNA derived from the human prostatic carcinoma ver-
sus normal prostate [1]. Later, the transcript of this ge-
ne was found in the prostatic carcinoma surgical samp-
les, prostatic carcinoma cell lines (LNCaP, DU145),
small-cell lung carcinoma (NCI-H69), breast carcino-
ma (T47D), colon carcinoma (SW-480), tumor cell li-
nes of hematopoietic origin, surgical specimens of pan-
creatic cancer and blood of patients with prostate can-
cer, but not in the normal and hypertrophic prostate tis-
sues [1–4]. Initially, the PTI-1 cDNA was reported to
consist of a 630 bp long 5' untranslated region (UTR)
similar to 23S ribosomal RNA of Mycoplasma hyo-
pneumoniae, and a coding region 98.4 % homologous
to the truncated and mutated form of translation elonga-
tion factor 1A1 (eEF1A1)mRNA [5, 6]. However, later
it was demonstrated that the PTI-1 transcript encodes
the truncated but not mutated form of eEF1A1[6]. In
the same work it was shown that the PTI-1 5'UTR (up
to 400 nt) can vary depending on the origin of genomic
DNA. Scaggiante’s group has detected a close corrella-
tion between the PTI-1 mRNA content and Mycoplas-
ma infection [7]. They have observed the PTI-1 trans-
cript only in cell lines and samples of prostate tumors
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infected with Mycoplasma. These data show that the
PTI-1 mRNA can be a product of trans-splicing or the
result of horizontal gene transfer due to chronicMyco-
plasma infection. Moreover, it should be noted that in-
fection withMycoplasma can enhance tumor invasive-
ness [8].
Since the amino acid sequence of the PTI-1 protein
has to be identical to eEF1A1 except for the lack of 67
amino acids fromN-terminus, the mechanism of its on-
cogenic action has been initially suggested to rely on its
interference with the eEF1A1 canonical and/or non-ca-
nonical functions [6]. However, the PTI-1 protein itself
has not been detected so far either in tumor tissues or
cell line extracts, including LNCaP, the cell line where
the presence of the PTI-1 transcript was originally de-
tected [6]. This can be partially explained by a poor Ko-
zak context of the PTI-1 mRNA initiator codon [6] and/
or presence of putative structural elements in its 5'UTR.
Thus, the oncogenicity of PTI-1 could be related to the
PTI-1 transcript itself [6].
We looked for structural elements in the 5'UTR of
PTI-1 mRNA that may potentially influence its transla-
tion. First, using a bioinformatics approach we found se-
veral structural elements in 5'UTR that might negati-
vely influence the PTI-1 mRNA translation. Second, we
found that upstream open reading frame (uORF) in the
5'UTR of the PTI-1 transcript was in more favorable
context for translation initiation than the main open rea-
ding frame (ORF). The homology analysis and tertiary
structure modeling showed that a peptide coding by
this uORF resembles the active center of relaxin, the
peptide hormone involved in the prostate cancer pro-
gression [9].
Materials and methods. Structural modeling. The
uPTI-1structure was modeled on the basis of the struc-
tures from Protein Data Bank (PDB) using Modeller
9.8 software [10]. The solution structure of omega-co-
notoxin GVIA (PDB code: 1OMC_A [11], residues
SER6-CYS8), jingzhaotoxin-VII (PDB code: 1ZJQ_A,
residues TYR20-LYS27), human relaxin (PDB code:
6RLX_B [12], residues ILE4-GLY20), ferredoxin chlo-
roplastic transit peptide (PDB code: 1FCT_A [13], resi-
dues ARG23-MET28) were used as templates for S4-
C6, Y9-K17, I18-G33, R36-M42 regions of uPTI-1, res-
pectively. Missed residues: M1-A3, T7-D8, Q11-T12,
N14, I16, S22, N24-V25, S27-L28, S30-P31, N34-L35
and T41were added using loops reconstruction option in
Modeller 9.8. Homology modeling with multiple temp-
lates protocol was used, 5000 structureswere generated.
The 5 best structures were selected using the Mo-
deller Objective Function (MOLPDF), the Discrete Op-
timized Protein Energy (DOPE) score and the norma-
lized DOPE score [14]. The selected structures were ve-
rified using the MolProbity web-server [15] to ensure
the absence of sterical clashes, unusual rotamers and
bonds, etc.
The protein modeling was performed using the in-
frastructure of the MolDynGrid [16] virtual laboratory
(http://moldyngrid.org), based on Nordugrid ARCMid-
dleware in the Ukrainian National Grid infrastructure
(http://grid.nas.gov.ua). VMD [17] was used for radius
gyration analysis, molecular graphics images were pro-
duced using the UCSF Chimera package for molecule
visualization [18].
Results and discussion. The PTI-1 mRNA may be
of low translation efficiency. Despite the detection of
the PTI-1 transcript in different cells and tissues, there
are no reports so far about the presence of a protein pro-
duct of this gene in the same samples. The only result
published up to date was the overexpression of c-myc-
tagged PTI-1 in HeLa cells [5]. A distinct band of the
c-myc-tagged PTI-1 protein was detected in cell extract
by anti-c-myc antibody. This result was further confir-
med by specific anti-eEF1A antibody which detected
overexpressed c-myc-tagged PTI as a discrete band mig-
rating slightly faster than the eEF1A protein [6]. It worth
noting, that the amount of recombinant PTI was low
comparing with endogenous eEF1A. This is also in ag-
reement with the result obtained for the PTI-1 mRNA
translation in a cell-free system [5]. It is known that a
start codon of the PTI-1 ORF is situated in a poor Ko-
zak context that may result in inefficient translation ini-
tiation and consequently small content of the protein in
cell. However even placing PTI-1 ORF in a proper Ko-
zak context resulted in weaker translation when compa-
red to the eEF1A protein pool [6].
The efficiency of mRNA translation depends not
only on the context of start codon, but also on the sequ-
ence and structure of 5'UTR [19, 20]. Thus, we checked
out the presence of additional elements in the PTI-1
5'UTR of mRNA that may potentially inhibit its trans-
lation, namely, long structured 5'UTR [21], presence of
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upstream start codons [22], and preferable uORFs [23].
The weakly translated transcripts, such as mRNAs of
hormones and growth factors, often have a long 5'UTR
with numerous secondary structures. The PTI-1 5'UTR
is extremely structured (Fig. 1, A) in contrast to the
5'UTR of mRNA coding for its homologue, eEF1A1
(Fig. 1, B). Using RNALfold [24] we analyzed the
5'UTR of PTI-1 mRNA. The RNA stem-loop structures
with G less than –30 kcal/mol in proximal to cap region
and lower than –50 kcal/mol in distal regions, which
can completely block the initiation of translation [25],
have not been found.
However, we observed several secondary structu-
res that can potentially inhibit the initiation of the PTI-1
mRNA translation (Fig. 1, A).
Upstream AUG was also shown to inhibit strongly
the translation of main ORF, especially if it is situated
in favorable context. In the 5'UTR of PTI-1 mRNA se-
ven upstream AUG (uAUG) codons were found (Fig.
1, A), three among them are in a strong Kozak context.
Thus, their competition with AUG codon of the main
PTI-1 ORF is highly possible. Preferable translation of
one of the uORFs may also have a negative effect on
translation of the main PTI-1 ORF. Indeed, the PTI-1
5'UTR contains 3 uORFs, two of them in a strong Ko-
zak context (Suppl., Fig. 1), in contrast to the main
ORF homologous with the eEF1A1.
Taking into account the data obtained, we have con-
cluded that the PTI-1 mRNA belongs most probably to
the class of templates with low efficiency of translation
due to the particular features of thePTI-1 5' UTR .
Searching for biologically relevant non-coding RNAs
in the 5'UTR of PTI-1 mRNA. Since the oncogenic me-
chanism that may be triggered by the PTI-1 protein is
doubtful, we looked more closely at the PTI-1 mRNA
as a possible source of other oncogenic factors. Earlier,
Fig. 1. A – secondary structure of the PTI-1 mRNA 5'UTR (upstream AUG codons marked by rectangles, elements of Kozak context marked by
circles); B – secondary structure of the eEF1A1 mRNA 5'UTR
an attempt to elucidate which part of the PTI-1 mRNA
is related to the tumor induction has been undertaken
[26].
In the nude mice model, no tumors were develo-
ped when animals were injected with the cells posses-
sing the 1–500 nt fragment of the 5'UTR (without 125
nt close to ORF) or the PTI-1 ORF itself that is homolo-
gous to the eEF1A1ORF. A negative effect was also ob-
served when the introduced cells carried the combina-
tion of abovementioned PTI-1 regions. The tumors we-
re developed only in the case of injecting the cells har-
boring the full PTI-1 cDNA, thus, possessing the 501–
625 nt region in the 5'UTR [26]. Based on aforemen-
tioned data one may conclude that just 501–625 nt re-
gion is responsible for the oncogenic properties of PTI-
1.What could be a possible mechanism of the oncogeni-
city of this PTI-1 mRNA fragment?
Firstly, the 501–625 bp PTI-1 mRNA region can be
a binding site for some trans-factors controlling mRNA
turnover and translation. In this case, the produced PTI-
1 mRNA could sequester these factors, thus, blocking
their cellular function. As a consequence, translation of
some proto-oncogenes mRNAs could be increased [27].
Secondly, this region can act as non-coding RNA, or ca-
talytic RNA, and target mRNAs of some oncosupres-
sors like in [28]. Besides, the PTI-1 mRNAmay contain
alternative uORFs coding for some oncoproteins.
To address first two issues we performed in silico
analysis of the 501–625 nt fragment of the PTI-1mRNA.
However, search for the regulatory motifs and structu-
res in the databases of known regulatory non-coding
RNAs [29–31] gave negative result (data not shown).
A peptide encoded by uORF present in the PTI-1
mRNA has structural similarity with the peptide hor-
mone relaxin.Asmentioned above, the 5'UTR of PTI-1
transcript has several uAUG codons in a better Kozak
context than AUG for the putative PTI-1 protein. Using
ORF finder [32], we checked whether these uAUG(s)
can be used as a start for a respective uORFs. The uAUG
codon in position 562–564 was situated in the most fa-
vorable Kozak context. The length of corresponding
uORF was 129 nt, thus, a putative translated peptide
(uPTI-1) should contain 42 amino acids.
The analysis of the uPTI-1 amino acid sequence
using TermiNator [33, 34] server confirmed that such
polypeptide may possess longer half-life and may be
more efficiently synthesized in comparison with the
PTI-1 protein (Suppl., Table 1). We performed the ho-
mology search in order to figure out a possible function
of this peptide. Using HHpred [35] we found that a part
of the uPTI-1 peptide sequence shares 53 % homology
with the B-chain of relaxin (Fig. 2), a peptide hormone
that is synthesized in prostate and was shown to promo-
te prostate cancer progression [36, 37]. Importantly, this
high homology sequence corresponds to the active cen-
ter of relaxin.
It has been shown that the location of conserved
RXXXRXX(I/V) motif on one side of the alpha-helix
of B-chain is an essential requirement for the interac-
tion of relaxin with its receptor [38]. For this reason we
performed the tertiary structure modeling of the uPTI-1
peptide to test whether it may resemble the relaxin ac-
tive center.
Using Modeller 9.8 we generated 5000 structures.
The structure number 1723 of the uPTI-1 peptide with
lowest DOPE andModeller Objective Function (MOF)
scores has the best quality values (Suppl., Fig. 2). The
radius of gyration (Rgyr) of modeled uPTI_1723 struc-
ture was 12.46 C and for relaxin «6RLX» was 7.78 C.
Difference in Rgyr between uPTI_1723 and 6RLX may
be explained by the various coordinate topology and
amino acid sequences of N-and C-terminus. However,
all selected structures testify for a globular structure of
the peptide.
As shown in Fig. 3, the model of the uPTI-1 peptide
structure resembles the relaxin B-chain structure. No-
tably, the H2 -helix of the uPTI-1 peptide, a seconda-
ry structure element required for the receptor binding,
is quite similar to the relaxin active center [38]. The on-
ly difference is the presence of arginine residue (R13)
in relaxin instead of serine residue (S27) in uPTI-1. It
should be mentioned that for effective receptor binding
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Fig. 2. Result of the uPTI-1 homology
search using HHPred. Numbers of residu-
es homologous to uPTI-1 are noted in bra-
ckets. The amino acid residues essential for
the function of relaxin are marked in bold
relaxin should contain both A and B chains.We believe
uPTI-1 preserves the possibility to interact with A-chain
of relaxin since it contains all cysteins responsible for
such interaction [39] (Fig. 3, C). However, it is still
questionable whether the uPTI-1 peptide requires A-
chain for relaxin receptor binding or it is able to ac-
tivate relaxin receptor by its own mechanism.
As relaxin is a peptide hormone it is secreted to the
extracellular environment. To verify if uPTI-1 can po-
tentially act as relaxin, we analyzed amino acid sequen-
ce of uPTI-1 by several programs that can predict loca-
lization of a protein [40–43], and all of them predicted
its extracellular localization (Suppl., Table 2).
In female, relaxin is produced by the corpus luteum
of the ovary, breast, placenta, chorion, and decidua du-
ring pregnancy. In male, it is synthesized in prostate
and is present in semen [44]. Importantly, relaxin was
shown to promote the prostate cancer progression [36,
37]. Moreover, the increased invasiveness and migra-
tion of the breast, endometrial, and thyroid adenocarci-
noma cells were induced by relaxin in vitro. These ef-
fects were accompanied by the up-regulation of matrix
metalloproteinase activity and vascular endothelial
growth factor expression, directly related to the cancer
progression [9, 45, 46]. The relaxin-like peptide family
belongs to the insulin superfamily and consists of 7 pep-
tides of high conformational but low sequence simila-
rity [47].
We believe that despite one amino acid substitu-
tion the uPTI-1 protein should be able to interact with
the relaxin receptor since its overall architecture re-
mains quite similar to relaxin and two other key amino
acid residues (R23 and I30) of the active center are con-
served (Fig. 3).
Conclusions. A novel mode of the PTI-1 oncogene
action is hypothesized, which has not yet been conside-
red but seems to be rather promising. The PTI-1 mRNA
may be regarded as a template for the relaxin-like pep-
tide synthesis. The uPTI-1 peptide may interact with the
respective relaxin-specific receptors, thus, promoting
the prostate cancer development via a relaxin-dependent
pathway.
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PTI-1: íîâèé øëÿõ ó÷àñò³ â îíêîãåíåç³
Ðåçþìå
Ìåòà. Îíêîãåí, ÿêèé ³íäóêóº ðàê ïðîñòàòè (PTI-1), ìîæå êîäóâà-
òè âêîðî÷åíó ôîðìó ôàêòîðà åëîíãàö³¿ eEF1A1. PTI-1 â³äêðèòî
ÿê ãåí, ùî íàäåêñïðåñóºòüñÿ ó çðàçêàõ ðàêó ïðîñòàòè ³ íå åêïðåñó-
ºòüñÿ ó íîðìàëüí³é òêàíèí³. Ìåõàí³çì îíêîãåííî¿ ä³¿ PTI-1 íà ñüî-
ãîäí³ çàëèøàºòüñÿ íåç’ÿñîâàíèì. Ìåòîäè. Á³î³íôîðìàòè÷í³ ìå-
òîäè çàñòîñîâàíî äëÿ àíàë³çó ñòðóêòóðè, åôåêòèâíîñò³ òðàíñëÿ-
ö³¿ ³ êîäóþ÷îãî ïîòåíö³àëó ìÐÍÊ PTI-1. Ðåçóëüòàòè. Àíàë³çîì in
silico 5'UTR ìÐÍÊ PTI-1 âèÿâëåíî, ùî çàçíà÷åíèé òðàíñêðèïò íà-
ëåæèòü äî êëàñó ìÐÍÊ ç íèçüêîþ åôåêòèâí³ñòþ òðàíñëÿö³¿. Äî-
äàòêîâî âèçíà÷åíî íîâó â³äêðèòó ðàìêó ç÷èòóâàííÿ (ORF), ÿêà ïî-
÷èíàºòüñÿ ç àëüòåðíàòèâíîãî ñòàðò-êîäîíó ³ ïåðåäóº îñíîâí³é
ORF. Ïåïòèä, ùî íå ìàº ãîìîëîã³¿ ç eEF1A1, àëå ÷àñòêîâî ãîìîëî-
ã³÷íèé ðåëàêñèíó, ïîòåíö³éíî ìîæå ñèíòåçóâàòèñÿ ç ö³º¿ àëüòåð-
íàòèâíî¿ ORF. Âèñíîâêè. Ìè ïðèïóñòèëè, ùî ç àëüòåðíàòèâíîãî
ñòàðò-êîäîíó ïî÷èíàºòüñÿ ñèíòåç ïåïòèäó (uPTI-1), ãîìîëîã³÷-
íîãî ðåëàêñèíó, – ãîðìîíó, ùî, ÿê â³äîìî, áåðå ó÷àñòü â ³íäóêö³¿ ðà-
êó ïðîñòàòè. Á³ëîê uPTI-1 ìîæå âçàºìîä³ÿòè ç â³äïîâ³äíèì ðåöåï-
òîðîì êë³òèíè, ñïåöèô³÷íèì äëÿ ðåëàêñèíó, ñïðè÷èíÿþ÷è ¿¿ òðàíñ-
ôîðìàö³þ. Òàêèì ÷èíîì, îíêîãåííà ä³ÿ ãåíà PTI-1 ìîæå ðåàë³çóâà-
òèñÿ ðåëàêñèí-îïîñåðåäêîâàíèì øëÿõîì.
Êëþ÷îâ³ ñëîâà: ðàê ïðîñòàòè, PTI-1, eEF1A1, íåêîäóþ÷à ÐÍÊ,
ðåëàêñèí, ORF, uAUG.
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Fig. 3. A – tertiary structure of relaxin B-chain; B – predicted tertiary
structure of uPTI-1 (exposed amino acids, essential for the relaxin func-
tioning, and sizes of alpha helixes are shown); C – secondary structure
analysis of uPTI-1 (upper structure) and of human relaxin 6RLX_B
(lower structure) performed by PDBsum web-server [47]. RXXXRXX
(I/V) motif similarity is shown using gray lines, cysteins that are res-
ponsible for interaction with A-chain marked with squares
À. À. Âèñëîâóõ, Â. Ô. Øàëàê, À. Â. Ñàâèöêèé, Í. È. Êîâàëåíêî,
Í. Ë. Ãðàëåâñêàÿ, Á. Ñ. Íåãðóöêèé, À. Â. Åëüñêàÿ
PTI-1: íîâûé ïóòü ó÷àñòèÿ â îíêîãåíåçå
Ðåçþìå
Öåëü. Îíêîãåí, èíäóöèðóþùèé ðàê ïðîñòàòû (PTI-1), ìîæåò êî-
äèðîâàòü óêîðî÷åííóþ ôîðìó ôàêòîðà ýëîíãàöèè eEF1A1. PTI-1
îòêðûò êàê ãåí, ñâåðõýêñïðåññèðóþùèéñÿ â îáðàçöàõ ðàêà ïðî-
ñòàòû è íå ýêñïðåññèðóþùèéñÿ â íîðìàëüíîé òêàíè. Ìåõàíèçì
îíêîãåííîãî äåéñòâèÿ PTI-1 íà ñåãîäíÿ îñòàåòñÿ íåèçâåñòíûì.
Ìåòîäû. Áèîèíôîðìàòè÷åñêèå ìåòîäû ïðèìåíåíû äëÿ àíàëèçà
ñòðóêòóðû, ýôôåêòèâíîñòè òðàíñëÿöèè è êîäèðóþùåãî ïîòåí-
öèàëà ìÐÍÊ PTI-1. Ðåçóëüòàòû. Ñ èñïîëüçîâàíèåì àíàëèçà in si-
lico 5'UTR ìÐÍÊ PTI-1 âèÿâëåíî, ÷òî óêàçàííûé òðàíñêðèïò
ïðèíàäëåæèò ê êëàññó ìÐÍÊ ñ íèçêîé ýôôåêòèâíîñòüþ òðàíñëÿ-
öèè. Äîïîëíèòåëüíî îïðåäåëåíà íîâàÿ îòêðûòàÿ ðàìêà ñ÷èòûâà-
íèÿ (ORF), íà÷èíàþùàÿñÿ ñ àëüòåðíàòèâíîãî ñòàðò-êîäîíà è íà-
õîäÿùàÿñÿ ïåðåä îñíîâíîé ORF. Ïåïòèä, íå èìåþùèé ãîìîëîãèè ñ
eEF1A1, íî ÷àñòè÷íî ãîìîëîãè÷íûé ðåëàêñèíó, ïîòåíöèàëüíî ìî-
æåò ñèíòåçèðîâàòüñÿ ñ ýòîé àëüòåðíàòèâíîé ORF. Âûâîäû.
Ìû ïðåäïîëîæèëè, ÷òî ñ àëüòåðíàòèâíîãî ñòàðò-êîäîíà íà÷è-
íàåòñÿ ñèíòåç ïåïòèäà (uPTI-1), ãîìîëîãè÷íîãî ðåëàêñèíó, – ãîð-
ìîíó, ó÷àñòâóþùåìó, êàê èçâåñòíî, â èíäóêöèè ðàêà ïðîñòàòû.
Áåëîê uPTI-1 ìîæåò âçàèìîäåéñòâîâàòü ñ ñîîòâåòñòâóþùèì
ðåöåïòîðîì êëåòêè, ñïåöèôè÷åñêèì äëÿ ðåëàêñèíà, ïðèâîäÿ ê åå
òðàíñôîðìàöèè. Òàêèì îáðàçîì, îíêîãåííîå äåéñòâèå ãåíà PTI-1
ìîæåò ðåàëèçîâàòüñÿ ðåëàêñèí-îïîñðåäîâàííûì ïóòåì.
Êëþ÷åâûå ñëîâà: ðàê ïðîñòàòû, PTI-1, eEF1A1, íåêîäèðóþ-
ùàÿ ÐÍÊ, ðåëàêñèí, ORF, uAUG.
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